CDK8-IN-13
CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 induces apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity[1].
Product Specifications
CAS Number
918523-75-8
UNSPSC
12352005
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk8-in-13.html
Purity
99.14
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CC(C2=CN=C3NC=CC3=C2)=C1)N
Molecular Formula
C14H11N3O
Molecular Weight
237.26
References & Citations
[1]Zhang XX, et al. Discovery of a novel oral type I CDK8 inhibitor against acute myeloid leukemia. Eur J Med Chem. 2023 May 5;251:115214.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK8
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Cadherin-17/LI-cadherin/CDH17 Monoclonal Antibody
Recombinant Human CD247/CD3-ZETA Protein (GST Tag)
Recombinant Human CD247/CD3-ZETA Protein (GST Tag)